Use of V(D)J recombination excision circles to identify T- and B-cell defects and to monitor the treatment in primary and acquired immunodeficiencies

• Published in: Journal of translational medicine Vol. 11; no. 1; p. 119
• Main Authors: Serana, Federico, Chiarini, Marco, Zanotti, Cinzia, Sottini, Alessandra, Bertoli, Diego, Bosio, Andrea, Caimi, Luigi, Imberti, Luisa
• Format: Journal Article
• Language: English
• Published: England BioMed Central 09.05.2013; BioMed Central Ltd
• Subjects: Adult; Anti-Retroviral Agents - therapeutic use; B-Lymphocytes - immunology; Bone marrow; Child; Child, Preschool; DNA, Circular - genetics; Flow Cytometry; HIV Infections - drug therapy; HIV Infections - immunology; Human immunodeficiency virus; Humans; Immune system; Immunologic Deficiency Syndromes - genetics; Immunology; Infant; Infant, Newborn; Kinases; Neonatal Screening; Proteins; Real-Time Polymerase Chain Reaction - methods; Receptors, Antigen, T-Cell - metabolism; Recombination, Genetic; Review; Stem Cell Transplantation; Stem Cells - cytology; T cell receptors; T-Lymphocytes - immunology; V(D)J Recombination
• ISSN: 1479-5876; 1479-5876
• DOI: 10.1186/1479-5876-11-119

T-cell receptor excision circles (TRECs) and kappa-deleting recombination excision circles (KRECs) are circular DNA segments generated in T and B cells during their maturation in the thymus and bone marrow. These circularized DNA elements persist in the cells, are unable to replicate, and are diluted as a result of cell division, thus are considered markers of new lymphocyte output. The quantification of TRECs and KRECs, which can be reliably performed using singleplex or duplex real-time quantitative PCR, provides novel information in the management of T- and B-cell immunity-related diseases. In primary immunodeficiencies, when combined with flow cytometric analysis of T- and B-cell subpopulations, the measure of TRECs and KRECs has contributed to an improved characterization of the diseases, to the identification of patients’ subgroups, and to the monitoring of stem cell transplantation and enzyme replacement therapy. For the same diseases, the TREC and KREC assays, introduced in the newborn screening program, allow early disease identification and may lead to discovery of new genetic defects. TREC and KREC levels can also been used as a surrogate marker of lymphocyte output in acquired immunodeficiencies. The low number of TRECs, which has in fact been extensively documented in untreated HIV-infected subjects, has been shown to increase following antiretroviral therapy. Differently, KREC number, which is in the normal range in these patients, has been shown to decrease following long-lasting therapy. Whether changes of KREC levels have relevance in the biology and in the clinical aspects of primary and acquired immunodeficiencies remains to be firmly established.